Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418

1.

Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.

Meddens MBM, Mennens SFB, Celikkol FB, Te Riet J, Kanger JS, Joosten B, Witsenburg JJ, Brock R, Figdor CG, Cambi A.

Front Immunol. 2018 Oct 9;9:2333. doi: 10.3389/fimmu.2018.02333. eCollection 2018.

2.

C-type lectin-like receptor 2 (CLEC-2)-dependent dendritic cell migration is controlled by tetraspanin CD37.

de Winde CM, Matthews AL, van Deventer S, van der Schaaf A, Tomlinson ND, Jansen E, Eble JA, Nieswandt B, McGettrick HM, Figdor CG, Tomlinson MG, Acton SE, van Spriel AB.

J Cell Sci. 2018 Oct 2;131(19). pii: jcs214551. doi: 10.1242/jcs.214551.

PMID:
30185523
3.

A comparative assessment of continuous production techniques to generate sub-micron size PLGA particles.

Operti MC, Fecher D, van Dinther EAW, Grimm S, Jaber R, Figdor CG, Tagit O.

Int J Pharm. 2018 Oct 25;550(1-2):140-148. doi: 10.1016/j.ijpharm.2018.08.044. Epub 2018 Aug 23.

PMID:
30144511
4.

Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells.

Wimmers F, Subedi N, van Buuringen N, Heister D, Vivié J, Beeren-Reinieren I, Woestenenk R, Dolstra H, Piruska A, Jacobs JFM, van Oudenaarden A, Figdor CG, Huck WTS, de Vries IJM, Tel J.

Nat Commun. 2018 Aug 20;9(1):3317. doi: 10.1038/s41467-018-05784-3.

5.

Dendritic cells in cancer immunotherapy.

Le Gall CM, Weiden J, Eggermont LJ, Figdor CG.

Nat Mater. 2018 Jun;17(6):474-475. doi: 10.1038/s41563-018-0093-6. No abstract available.

PMID:
29795222
6.

Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8+ T Cell Activation.

Qiu L, Valente M, Dolen Y, Jäger E, Beest MT, Zheng L, Figdor CG, Verdoes M.

Small. 2018 Apr;14(15):e1703539. doi: 10.1002/smll.201703539. Epub 2018 Mar 1.

PMID:
29493121
7.

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.

Gorris MAJ, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe IN, Verweij D, Wortel IMN, Textor JC, de Vries IJM, Figdor CG.

J Immunol. 2018 Jan 1;200(1):347-354. doi: 10.4049/jimmunol.1701262. Epub 2017 Nov 15.

PMID:
29141863
8.

Migrating into the Tumor: a Roadmap for T Cells.

van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM.

Trends Cancer. 2017 Nov;3(11):797-808. doi: 10.1016/j.trecan.2017.09.006. Epub 2017 Nov 6. Review.

PMID:
29120755
9.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG.

Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15.

10.

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.

Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ.

Oncotarget. 2017 May 7;8(33):54434-54443. doi: 10.18632/oncotarget.17661. eCollection 2017 Aug 15.

11.

Synthetic immune niches for cancer immunotherapy.

Weiden J, Tel J, Figdor CG.

Nat Rev Immunol. 2018 Mar;18(3):212-219. doi: 10.1038/nri.2017.89. Epub 2017 Aug 30. Review.

PMID:
28853444
12.

Affinity-Based Purification of Polyisocyanopeptide Bioconjugates.

Hammink R, Eggermont LJ, Zisis T, Tel J, Figdor CG, Rowan AE, Blank KG.

Bioconjug Chem. 2017 Oct 18;28(10):2560-2568. doi: 10.1021/acs.bioconjchem.7b00398. Epub 2017 Sep 15.

PMID:
28846388
13.

N-glycan mediated adhesion strengthening during pathogen-receptor binding revealed by cell-cell force spectroscopy.

Te Riet J, Joosten B, Reinieren-Beeren I, Figdor CG, Cambi A.

Sci Rep. 2017 Jul 27;7(1):6713. doi: 10.1038/s41598-017-07220-w.

14.

A membrane-anchored aptamer sensor for probing IFNγ secretion by single cells.

Qiu L, Wimmers F, Weiden J, Heus HA, Tel J, Figdor CG.

Chem Commun (Camb). 2017 Jul 13;53(57):8066-8069. doi: 10.1039/c7cc03576d.

PMID:
28675396
15.

Controlling T-Cell Activation with Synthetic Dendritic Cells Using the Multivalency Effect.

Hammink R, Mandal S, Eggermont LJ, Nooteboom M, Willems PH, Tel J, Rowan AE, Figdor CG, Blank KG.

ACS Omega. 2017 Mar 31;2(3):937-945. doi: 10.1021/acsomega.6b00436. Epub 2017 Mar 16.

16.

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.

Mathan TSM, Textor J, Sköld AE, Reinieren-Beeren I, van Oorschot T, Brüning M, Figdor CG, Buschow SI, Bakdash G, de Vries IJM.

Oncotarget. 2017 Mar 21;8(12):19879-19893. doi: 10.18632/oncotarget.15190.

17.

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2017 Mar;12(5):491-510. doi: 10.2217/nnm-2016-0295. Epub 2017 Feb 9.

PMID:
28181470
18.

Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function.

Worah K, Mathan TSM, Vu Manh TP, Keerthikumar S, Schreibelt G, Tel J, Duiveman-de Boer T, Sköld AE, van Spriel AB, de Vries IJM, Huynen MA, Wessels HJ, Gloerich J, Dalod M, Lasonder E, Figdor CG, Buschow SI.

Cell Rep. 2016 Sep 13;16(11):2953-2966. doi: 10.1016/j.celrep.2016.08.023.

19.

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

Boudewijns S, Koornstra RH, Westdorp H, Schreibelt G, van den Eertwegh AJ, Geukes Foppen MH, Haanen JB, de Vries IJ, Figdor CG, Bol KF, Gerritsen WR.

Oncoimmunology. 2016 Jun 17;5(8):e1201625. doi: 10.1080/2162402X.2016.1201625. eCollection 2016 Aug.

20.

Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.

Di Blasio S, Wortel IM, van Bladel DA, de Vries LE, Duiveman-de Boer T, Worah K, de Haas N, Buschow SI, de Vries IJ, Figdor CG, Hato SV.

Oncoimmunology. 2016 Aug 3;5(8):e1192739. doi: 10.1080/2162402X.2016.1192739. eCollection 2016 Aug.

21.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ.

Oncoimmunology. 2016 May 31;5(7):e1191732. doi: 10.1080/2162402X.2016.1191732. eCollection 2016 Jul.

22.

Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma.

Vasaturo A, Di Blasio S, Verweij D, Blokx WA, van Krieken JH, de Vries IJ, Figdor CG.

Histopathology. 2017 Mar;70(4):643-649. doi: 10.1111/his.13070. Epub 2016 Dec 2.

PMID:
27571246
23.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kiliç E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJ.

Ophthalmology. 2016 Oct;123(10):2265-7. doi: 10.1016/j.ophtha.2016.06.027. Epub 2016 Jul 29. No abstract available.

PMID:
27476772
24.

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Sköld AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T, Schröder C, Smits EL, Figdor CG, de Vries IJ.

Cancer Res. 2016 Aug 1;76(15):4332-46. doi: 10.1158/0008-5472.CAN-15-1695. Epub 2016 Jun 20.

25.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.

Boudewijns S, Westdorp H, Koornstra RH, Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de Vries IJ, Gerritsen WR, Bol KF.

J Immunother. 2016 Jul-Aug;39(6):241-8. doi: 10.1097/CJI.0000000000000127.

26.

T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.

Vasaturo A, Halilovic A, Bol KF, Verweij DI, Blokx WA, Punt CJ, Groenen PJ, van Krieken JH, Textor J, de Vries IJ, Figdor CG.

Cancer Res. 2016 Jun 15;76(12):3496-506. doi: 10.1158/0008-5472.CAN-15-3211. Epub 2016 Apr 11.

27.

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.

Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG.

Clin Cancer Res. 2016 Apr 15;22(8):1897-906. doi: 10.1158/1078-0432.CCR-15-1399. Review.

28.

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.

Tel J, Koornstra R, de Haas N, van Deutekom V, Westdorp H, Boudewijns S, van Erp N, Di Blasio S, Gerritsen W, Figdor CG, de Vries IJ, Hato SV.

J Transl Med. 2016 Apr 14;14:88. doi: 10.1186/s12967-016-0844-6.

29.

Opportunities for immunotherapy in microsatellite instable colorectal cancer.

Westdorp H, Fennemann FL, Weren RD, Bisseling TM, Ligtenberg MJ, Figdor CG, Schreibelt G, Hoogerbrugge N, Wimmers F, de Vries IJ.

Cancer Immunol Immunother. 2016 Oct;65(10):1249-59. doi: 10.1007/s00262-016-1832-7. Epub 2016 Apr 8. Review.

30.

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets.

Sittig SP, Bakdash G, Weiden J, Sköld AE, Tel J, Figdor CG, de Vries IJ, Schreibelt G.

Mediators Inflamm. 2016;2016:3605643. doi: 10.1155/2016/3605643. Epub 2016 Feb 7.

31.

Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses.

Dölen Y, Kreutz M, Gileadi U, Tel J, Vasaturo A, van Dinther EA, van Hout-Kuijer MA, Cerundolo V, Figdor CG.

Oncoimmunology. 2015 Aug 12;5(1):e1068493. eCollection 2016.

32.

Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ.

Oncoimmunology. 2015 Aug 12;5(1):e1067745. eCollection 2016.

33.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ.

Oncoimmunology. 2015 Jun 5;5(1):e1057673. eCollection 2016.

34.

Lipid peroxidation causes endosomal antigen release for cross-presentation.

Dingjan I, Verboogen DR, Paardekooper LM, Revelo NH, Sittig SP, Visser LJ, Mollard GF, Henriet SS, Figdor CG, Ter Beest M, van den Bogaart G.

Sci Rep. 2016 Feb 24;6:22064. doi: 10.1038/srep22064.

35.

Proteome Based Construction of the Lymphocyte Function-Associated Antigen 1 (LFA-1) Interactome in Human Dendritic Cells.

Eich C, Lasonder E, Cruz LJ, Reinieren-Beeren I, Cambi A, Figdor CG, Buschow SI.

PLoS One. 2016 Feb 18;11(2):e0149637. doi: 10.1371/journal.pone.0149637. eCollection 2016.

36.

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, Oyen WJ, Boerman OC, Mus RD, van Rossum MM, van der Graaf CA, Punt CJ, Adema GJ, Figdor CG, de Vries IJ, Schreibelt G.

Cancer Immunol Immunother. 2016 Mar;65(3):327-39. doi: 10.1007/s00262-016-1796-7. Epub 2016 Feb 10.

37.

Tetraspanin CD37 protects against the development of B cell lymphoma.

de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, Jabbar KJ, van den Brand M, van der Schaaf A, Elfrink S, van Houdt IS, Gijbels MJ, van de Loo FA, Bennink MB, Hebeda KM, Groenen PJ, van Krieken JH, Figdor CG, van Spriel AB.

J Clin Invest. 2016 Feb;126(2):653-66. doi: 10.1172/JCI81041. Epub 2016 Jan 19.

38.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokx WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, Blank CU, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ.

Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28.

39.

Semaphorin 7A Promotes Chemokine-Driven Dendritic Cell Migration.

van Rijn A, Paulis L, te Riet J, Vasaturo A, Reinieren-Beeren I, van der Schaaf A, Kuipers AJ, Schulte LP, Jongbloets BC, Pasterkamp RJ, Figdor CG, van Spriel AB, Buschow SI.

J Immunol. 2016 Jan 1;196(1):459-68. doi: 10.4049/jimmunol.1403096. Epub 2015 Nov 23.

40.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.

Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Mus RD, Croockewit SA, Jacobs JF, Schuler G, Neyns B, Austyn JM, Punt CJ, Schreibelt G, de Vries IJ.

Oncoimmunology. 2015 Apr 1;4(8):e1019197. eCollection 2015 Aug.

41.

Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists.

Kreutz M, Bakdash G, Dolen Y, Sköld AE, van Hout-Kuijer MA, de Vries IJ, Figdor CG.

Eur J Immunol. 2015 Oct;45(10):2798-809. doi: 10.1002/eji.201545583. Epub 2015 Sep 2.

42.

PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI.

Srinivas M, Tel J, Schreibelt G, Bonetto F, Cruz LJ, Amiri H, Heerschap A, Figdor CG, de Vries IJ.

Nanomedicine (Lond). 2015;10(15):2339-48. doi: 10.2217/NNM.15.76. Epub 2015 Aug 7.

PMID:
26251876
43.

The tetraspanin web revisited by super-resolution microscopy.

Zuidscherwoude M, Göttfert F, Dunlock VM, Figdor CG, van den Bogaart G, van Spriel AB.

Sci Rep. 2015 Jul 17;5:12201. doi: 10.1038/srep12201.

44.

Selective Expression of the MAPK Phosphatase Dusp9/MKP-4 in Mouse Plasmacytoid Dendritic Cells and Regulation of IFN-β Production.

Niedzielska M, Raffi FA, Tel J, Muench S, Jozefowski K, Alati N, Lahl K, Mages J, Billmeier U, Schiemann M, Appelt UK, Wirtz S, Sparwasser T, Hochrein H, Figdor CG, Keyse SM, Lang R.

J Immunol. 2015 Aug 15;195(4):1753-62. doi: 10.4049/jimmunol.1400658. Epub 2015 Jul 13.

45.

AFM force spectroscopy reveals how subtle structural differences affect the interaction strength between Candida albicans and DC-SIGN.

te Riet J, Reinieren-Beeren I, Figdor CG, Cambi A.

J Mol Recognit. 2015 Nov;28(11):687-98. doi: 10.1002/jmr.2481. Epub 2015 May 26.

PMID:
26011000
46.

Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs.

de Winde CM, Zuidscherwoude M, Vasaturo A, van der Schaaf A, Figdor CG, van Spriel AB.

Histochem Cell Biol. 2015 Aug;144(2):133-46. doi: 10.1007/s00418-015-1326-2. Epub 2015 May 8.

47.

Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.

Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, Van Tendeloo VF, de Vries IJ, Adema GJ, Berneman ZN, Smits EL.

Cancer Immunol Immunother. 2015 Jul;64(7):831-42. doi: 10.1007/s00262-015-1688-2. Epub 2015 Apr 12.

PMID:
25863943
48.

Design of a highly selective quenched activity-based probe and its application in dual color imaging studies of cathepsin S activity localization.

Oresic Bender K, Ofori L, van der Linden WA, Mock ED, Datta GK, Chowdhury S, Li H, Segal E, Sanchez Lopez M, Ellman JA, Figdor CG, Bogyo M, Verdoes M.

J Am Chem Soc. 2015 Apr 15;137(14):4771-7. doi: 10.1021/jacs.5b00315. Epub 2015 Apr 1.

49.

Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread.

Büll C, Boltje TJ, van Dinther EA, Peters T, de Graaf AM, Leusen JH, Kreutz M, Figdor CG, den Brok MH, Adema GJ.

ACS Nano. 2015 Jan 27;9(1):733-45. doi: 10.1021/nn5061964. Epub 2015 Jan 14.

PMID:
25575241
50.

Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.

Vasaturo A, Verdoes M, de Vries J, Torensma R, Figdor CG.

Immunobiology. 2015 Feb;220(2):243-8. doi: 10.1016/j.imbio.2014.11.007. Epub 2014 Nov 15. Review.

PMID:
25466585

Supplemental Content

Loading ...
Support Center